VG Life Sciences Inc. income statement BIOM

Annual Quarterly

In fiscal 2014, which ended Dec 31, 2014, VG Life Sciences Inc. reported revenue of $0. It recorded a net loss of $6.2 million. Over the twelve months ended Sep 30, 2015, revenue was $0 and the net loss was $4.3 million.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2015
Sep 30, 2015
FY 2014
Dec 31, 2014
Revenue
0
0
Research and development
0
1
Selling, general and administrative
1
1
Operating income
-3
-4
Income tax
—
0
Net income
-4
-6
Other measures
Depreciation and amortization
—
0
EBITDA
—
-4
Interest coverage
-1.32x
-1.50x
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BIOM (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Miami, FL
SEC filer status
Smaller reporting company
SEC CIK
1091326
Former names
SB Technology Holdings, Inc. (until May 4, 2026); VG Life Sciences Inc. (until Mar 6, 2026); VG Life Sciences, Inc. (until Oct 14, 2014); VIRAL GENETICS INC /DE/ (until Mar 25, 2009); 5 STARLIVING ONLINE INC (until Oct 18, 2001)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.